Therapeutic Peptides Produced Through
approved in 1982 (51 amino acids)
approved in 2002 (32 amino acids)
approved in 2009 (60 amino acids)
approved in 2012 (33 amino acids)
Purification Challenges That We Solve
The purification of recombinant peptides is challenging, as these molecules are prone to self-aggregation and fibrillation. The peptide fibrils block the mobile phase flow in the HPLC column diminishing resolution, worsening separation and raising the column back pressure. Simply packing fresh silica is economically unfeasible and re-packing the column will mechanically damage the silica particles.
The best solution is CIP with NaOH solution; the double action of NaOH cleaving the fibrils and the desorption by the organic solvent (such as acetonitrile) results in the successful removal of the fibrils from the column. DAISOGEL offers two series of silica gel that provide the required alkaline stability for sustained recombinant peptide purification, including our newest premium phase.
Did you know?
Led by long-acting insulins, the market size for recombinant insulin is expected to grow from $27B in 2018 to $48B in 2026.